BackBridgeBio Oncology Therapeutics Overview

BridgeBio Oncology Therapeutics Current Cash

Track BridgeBio Oncology Therapeutics's current cash ($54M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$54.06M
↑ 8039.19% YoYΔ $53.40M vs prior year quarter

Peer trimmed avg / median

Loading

BridgeBio Oncology Therapeutics Current Cash History

Loading

BridgeBio Oncology Therapeutics vs. peers: Current Cash Comparison

Loading

BridgeBio Oncology Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BridgeBio Oncology Therapeutics (BBOT) FAQ

As of the most recent data (June 2026), BBOT shows a current cash of $54M. That compares with $660K in the prior-year period — up 8039.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BBOT's current cash is now $54M (was $660K) — a 8039.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BridgeBio Oncology Therapeutics is outperforming or lagging.

Tracking BBOT's current cash over time shows whether BridgeBio Oncology Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $54M That compares with $660K in the prior-year period — up 8039.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has BridgeBio Oncology Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $54M) with ownership activity and broader fundamentals.